The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Impact of tumor growth rate during preceding treatment on tumor response to nivolumab or irinotecan in advanced gastric cancer.
 
Kyoko Kato
No Relationships to Disclose
 
Toshiki Masuishi
Honoraria - Chugai Pharma; Lilly; Merck Serono; Taiho Pharmaceutical; Takeda; Yakult Honsha
 
Kunihiro Fushiki
No Relationships to Disclose
 
Shintaro Nakano
No Relationships to Disclose
 
Takeshi Kawakami
Honoraria - Chugai Pharma; Lilly Japan; Merck Serono; Taiho Pharmaceutical; Takeda
 
Yasuyuki Kawamoto
Honoraria - Sawai Pharmaceutical Co; Taiho Pharmaceutical; Takeda
Research Funding - Japan Agency for Medical Research and Development
 
Yukiya Narita
Speakers' Bureau - Bristol-Myers Squibb; Chugai Pharma; Lilly; Ono Pharmaceutical; Taiho Pharmaceutical; Takeda
Research Funding - Bristol-Myers Squibb; Ono Pharmaceutical
 
Takahiro Tsushima
Honoraria - Chugai Pharma; Ono Pharmaceutical; Taiho Pharmaceutical; Takeda
 
Hiroshi Nakatsumi
Honoraria - Bayer Yakuhin; Lilly Japan; Ono Pharmaceutical
 
Shigenori Kadowaki
Research Funding - Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Lilly Japan (Inst); Ono Pharmaceutical (Inst); Taiho Pharmaceutical (Inst)
 
Akiko Todaka
Consulting or Advisory Role - Daiichi Sankyo; Taiho Pharmaceutical; Yakult Honsha
 
Satoshi Yuki
Honoraria - Bayer Yakuhin; Bristol-Myers Squibb Japan; Chugai Pharma; Lilly Japan; Merck Serono; Ono Pharmaceutical; Sanofi; Taiho Pharmaceutical; Takeda; Yakult Honsha
 
Masahiro Tajika
Speakers' Bureau - Ajinomoto
Research Funding - Ajinomoto (Inst)
 
Nozomu Machida
Speakers' Bureau - Taiho Pharmaceutical
Research Funding - MSD
 
Yoshito Komatsu
Honoraria - Bayer; Novartis; Pfizer
Speakers' Bureau - Bayer; Bristol-Myers Squibb Japan; Chugai Pharma; Daiichi Sankyo; Lilly; Merck Serono; Nipro Corporation; Novartis; Ono Pharmaceutical; Pfizer; Sanofi; Taiho Pharmaceutical; Takeda; TOWA; Yakult Honsha
Research Funding - Astellas Pharma; Bayer; Boehringer Ingelheim; Chugai Pharma; Dainippon Sumitomo Pharma; Eisai; Lilly; MSD; Novartis; Ono Pharmaceutical; Sanofi; Sysmex; Taiho Pharmaceutical; Takeda; Yakult Pharmaceutical
 
Kei Muro
Honoraria - Bayer; Chugai Pharma; Lilly; Merck Serono; Ono Pharmaceutical; Taiho Pharmaceutical; Takeda; Yakult Honsha
Research Funding - Daiichi Sankyo (Inst); Gilead Sciences (Inst); Kyowa Hakko Kirin (Inst); Merck Serono (Inst); MSD (Inst); Ono Pharmaceutical (Inst); Pfizer (Inst); Sanofi (Inst); Shionogi (Inst)
 
Hirofumi Yasui
No Relationships to Disclose